These studies would confirm whether RUNX3 down-regulation drives VOC or is a secondary effect, elucidate mechanistic pathways, validate biomarker reliability across diverse SCD populations, and explore therapeutic potential (e.g., via gene therapy). The gene discussed is RUNX3; the disease is Schnyder corneal dystrophy.